Pfizer Inc.

51.60+1.51+3.01%Vol 15.70M1Y Perf 27.81%
Jun 24th, 2022 15:59 DELAYED
BID50.98 ASK51.70
Open50.65 Previous Close50.09
Pre-Market- After-Market51.50
 - -  -0.09 -0.17%
Target Price
60.50 
Analyst Rating
Moderate Buy 1.67
Potential %
17.25 
Finscreener Ranking
★★+     48.46
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     52.26
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.48
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★+     47.89
Price Range Ratio 52W %
55.83 
Earnings Rating
Strong Sell
Market Cap289.52B 
Earnings Date
28th Jul 2022
Alpha0.01 Standard Deviation0.07
Beta0.76 

Today's Price Range

50.3051.64

52W Range

38.8261.71

5 Year PE Ratio Range

8.9036.10

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
10.90%
1 Month
-3.93%
3 Months
-2.24%
6 Months
-12.11%
1 Year
27.81%
3 Years
17.92%
5 Years
51.01%
10 Years
158.51%

TickerPriceChg.Chg.%
PFE51.601.51003.01
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.40
0.29
0.43
22.70
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
60.40
31.30
36.90
9.70
27.11
RevenueValueIndustryS&P 500US Markets
92.37B
16.46
14.63
6.29
DividendsValueIndustryS&P 500US Markets
3.44
1.60
3.87
5.00
Payout ratio92.00
Earnings HistoryEstimateReportedSurprise %
Q01 20221.661.62-2.41
Q04 20210.851.0827.06
Q03 20211.081.3424.07
Q02 20210.971.0710.31
Q01 20210.790.9317.72
Q04 20200.460.42-8.70
Q03 20200.700.722.86
Q02 20200.640.7821.88
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.87-19.05Negative
9/2022 QR1.93-15.72Negative
12/2022 FY6.61-8.19Negative
12/2023 FY5.399.11Positive
Next Report Date28th Jul 2022
Estimated EPS Next Report1.95
Estimates Count5
EPS Growth Next 5 Years %12.50
Volume Overview
Volume15.70M
Shares Outstanding5.61M
Shares Float5.61B
Trades Count116.88K
Dollar Volume800.70M
Avg. Volume23.87M
Avg. Weekly Volume24.81M
Avg. Monthly Volume22.80M
Avg. Quarterly Volume24.01M

Pfizer Inc. (NYSE: PFE) stock closed at 51.59 per share at the end of the most recent trading day (a 3.01% change compared to the prior day closing price) with a volume of 15.70M shares and market capitalization of 289.52B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 78500 people. Pfizer Inc. CEO is Albert Bourla.

The one-year performance of Pfizer Inc. stock is 27.81%, while year-to-date (YTD) performance is -12.62%. PFE stock has a five-year performance of 51.01%. Its 52-week range is between 38.82 and 61.71, which gives PFE stock a 52-week price range ratio of 55.83%

Pfizer Inc. currently has a PE ratio of 10.70, a price-to-book (PB) ratio of 3.17, a price-to-sale (PS) ratio of 2.83, a price to cashflow ratio of 7.70, a PEG ratio of 2.32, a ROA of 14.96%, a ROC of 23.27% and a ROE of 33.92%. The company’s profit margin is 27.11%, its EBITDA margin is 36.90%, and its revenue ttm is $92.37 Billion , which makes it $16.46 revenue per share.

Of the last four earnings reports from Pfizer Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.95 for the next earnings report. Pfizer Inc.’s next earnings report date is 28th Jul 2022.

The consensus rating of Wall Street analysts for Pfizer Inc. is Moderate Buy (1.67), with a target price of $60.5, which is +17.25% compared to the current price. The earnings rating for Pfizer Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Pfizer Inc. has a dividend yield of 3.44% with a dividend per share of $1.60 and a payout ratio of 92.00%.

Pfizer Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 7.21, ATR14 : 1.51, CCI20 : 7.00, Chaikin Money Flow : 0.01, MACD : -0.60, Money Flow Index : 48.94, ROC : -4.39, RSI : 55.00, STOCH (14,3) : 64.13, STOCH RSI : 1.00, UO : 57.88, Williams %R : -35.87), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Pfizer Inc. in the last 12-months were: Alexander R. Mackenzie (Sold 41 360 shares of value $2 244 193 ), Angela Hwang (Option Excercise at a value of $325 530), Angela Hwang (Sold 26 170 shares of value $1 298 002 ), Douglas M. Lankler (Option Excercise at a value of $1 989 350), Douglas M. Lankler (Sold 78 273 shares of value $4 065 854 ), Frank A. D'Amelio (Option Excercise at a value of $3 255 296), Jennifer B. Damico (Option Excercise at a value of $569 843), Jennifer B. Damico (Sold 12 379 shares of value $616 980 ), John Douglas Young (Sold 150 000 shares of value $7 508 731 ), Michael McDermott (Option Excercise at a value of $315 904), Mikael Dolsten (Option Excercise at a value of $8 275 962), Mikael Dolsten (Sold 123 566 shares of value $6 152 193 ), Payal Sahni (Sold 1 408 shares of value $70 175 ), Rady A. Johnson (Option Excercise at a value of $750 515), Rady A. Johnson (Sold 19 000 shares of value $1 015 042 ), Sally Susman (Option Excercise at a value of $1 627 648), Sally Susman (Sold 43 608 shares of value $2 377 434 ), William R. Carapezzi (Option Excercise at a value of $542 541), William R. Carapezzi (Sold 32 908 shares of value $1 645 400 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
8 (72.73 %)
8 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (33.33 %)
3 (27.27 %)
4 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Strong Buy
1.55
Moderate Buy
1.67

Pfizer Inc.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.

CEO: Albert Bourla

Telephone: +1 212 733-2323

Address: 235 East 42nd Street, New York 10017, NY, US

Number of employees: 78 500

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

56%44%

Bearish Bullish

54%46%

TipRanks News for PFE

Wed, 08 Jun 2022 23:01 GMT Pfizer Stock: Innovation at a Very Reasonable Price

- TipRanks. All rights reserved.

Thu, 26 May 2022 03:06 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), uniQure (QURE) and Aldeyra Therapeutics (ALDX)

- TipRanks. All rights reserved.

Wed, 25 May 2022 12:55 GMT Pfizer (PFE) Gets a Hold Rating from Goldman Sachs

- TipRanks. All rights reserved.

Tue, 24 May 2022 02:07 GMT Pfizer (PFE) Initiated with a Hold at SVB Securities

- TipRanks. All rights reserved.

Mon, 23 May 2022 13:55 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE) and Concert Pharma (CNCE)

- TipRanks. All rights reserved.

Thu, 19 May 2022 12:20 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and TFF Pharmaceuticals (TFFP)

- TipRanks. All rights reserved.

Tue, 17 May 2022 12:55 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and 9 Meters Biopharma (NMTR)

- TipRanks. All rights reserved.

Tue, 17 May 2022 01:15 GMT Pfizer (PFE) Receives a Hold from Credit Suisse

- TipRanks. All rights reserved.

Wed, 04 May 2022 16:33 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Apollo Endosurgery (APEN) and Biogen (BIIB)

- TipRanks. All rights reserved.

Wed, 04 May 2022 12:53 GMT Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Henry Schein (HSIC)

- TipRanks. All rights reserved.

Wed, 04 May 2022 09:10 GMT Is Pfizer Stock worth Considering Post Upbeat Q1 Results

- TipRanks. All rights reserved.

Tue, 03 May 2022 23:32 GMT This Analyst Says to Be Positive About Novavaxs Covid Vaccine Chances

- TipRanks. All rights reserved.

Tue, 03 May 2022 13:50 GMT Pfizer (PFE) Receives a Hold from J.P. Morgan

- TipRanks. All rights reserved.

Mon, 02 May 2022 08:22 GMT Will Pfizers Q1 Results Provide the Much-Needed Boost to the Stock

- TipRanks. All rights reserved.

Fri, 15 Apr 2022 03:25 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Alaunos Therapeutics (TCRT)

- TipRanks. All rights reserved.

Fri, 08 Apr 2022 13:55 GMT Pfizer to Bolster RSV Vaccination Through Acquisition

- TipRanks. All rights reserved.

Fri, 01 Apr 2022 15:16 GMT Pfizer Stock: Can Booster Season Boost Shares

- TipRanks. All rights reserved.

Mon, 28 Mar 2022 18:11 GMT Pfizer Stock: What Upside Remains

- TipRanks. All rights reserved.

Fri, 25 Mar 2022 09:58 GMT Pfizer Receives FDA Breakthrough Therapy Designation for RSVpreF

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 15:51 GMT Eli Lilly Stock: Not Attractive Relative to Peers

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 09:11 GMT Understanding Pfizers Newly Added Risk Factors

- TipRanks. All rights reserved.

Tue, 01 Mar 2022 16:44 GMT Why Pfizer Is Set to Make Investors Happy

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 10:19 GMT Biohaven & Pfizer Bags CHMP Positive Recommendation for Rimegepant

- TipRanks. All rights reserved.

Thu, 10 Feb 2022 23:08 GMT Pfizer Stock: Room for Upside, but Long-Term Uncertainty Remains

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 15:26 GMT Pfizer (PFE) Gets a Hold Rating from Barclays

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 08:17 GMT Pfizer Falls 6.6% on Q4 Earnings Beat and Revenue Miss

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 08:00 GMT Novavax Dives After Vaccine Delivery Numbers Falter

- TipRanks. All rights reserved.

Wed, 09 Feb 2022 07:46 GMT Pfizer Slips on Mixed Earnings Report

- TipRanks. All rights reserved.

Fri, 28 Jan 2022 20:17 GMT Pfizer: Strong Vaccine Revenues, but Watch the Valuation

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 12:37 GMT Pfizer (PFE) Receives a Hold from Mizuho Securities

- TipRanks. All rights reserved.

Mon, 24 Jan 2022 15:10 GMT Pfizer CEO Sees Annual COVID-19 Vaccine Preferable to Booster Shots

- TipRanks. All rights reserved.

Mon, 17 Jan 2022 08:22 GMT GlaxoSmithKline (GSK) Rejects Unilever

- TipRanks. All rights reserved.

Fri, 14 Jan 2022 16:19 GMT In Search of a Better Covid Vaccine, This Analyst Taps Ocugen

- TipRanks. All rights reserved.

Thu, 13 Jan 2022 19:15 GMT Pfizer Stock: Discounted Valuation Multiples

- TipRanks. All rights reserved.

Mon, 03 Jan 2022 10:52 GMT U.K. Approves Pfizers Paxlovid Shares Rise Report

- TipRanks. All rights reserved.

News

Stocktwits